Greenwich LifeSciences, Inc. (GLSI)
After hours:
| Previous close | 16.62 |
| Open | 16.80 |
| Bid | 15.82 x 100 |
| Ask | 16.34 x 100 |
| Day's range | 15.94 - 16.92 |
| 52-week range | 7.58 - 21.44 |
| Volume | |
| Avg. volume | 45,480 |
| Market cap | 208.27M |
| Beta (5Y monthly) | 3.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings date | 21 Aug 2024 - 25 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.00 |
GlobeNewswireGreenwich LifeSciences Set to Join Russell 2000 Index Again
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, accordin
GuruFocus.comInsider Buying: CEO and CFO Snehal Patel Acquires Shares of Greenwich LifeSciences Inc (GLSI)
Snehal Patel, CEO, CFO, and 10% Owner of Greenwich LifeSciences Inc (NASDAQ:GLSI), purchased 174,825 shares of the company on June 13, 2024.
- GlobeNewswire
Greenwich LifeSciences Announces $2.5 Million Private Placement
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a p
